Tokyo, Jan. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060325) titled 'Clinical results of romosozumab in the treatment of osteoporosis' on Jan. 12.
Study Type:
Observational
Primary Sponsor:
Institute - Niimi orthopaedics clinic
Condition:
Condition - Osteoporosis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the treatment outcomes of romosozumab in real-world clinical practice.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 30
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Severe osteoporosis
Key exclusion criteria - 1) a history of myocardial infarction or stroke
2) a history of hypersensitivity to romosozumab or its components
3) pregnancy, suspected pregnancy, or breastfeeding
4) failure to obtain written informed consent for participation in the study
Target Size - 500
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2019 Year 01 Month 01 Day
Date of IRB - 2025 Year 12 Month 30 Day
Anticipated trial start date - 2019 Year 03 Month 04 Day
Last follow-up date - 2035 Year 12 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069005
Disclaimer: Curated by HT Syndication.
